Is this a scaled health distributor?
McKesson is a large U.S. health care company best known for pharmaceutical distribution. It moves high volumes of medicines and related health products through a logistics network that connects manufacturers to pharmacies, hospitals, and other care settings. The business is built around being a reliable, scaled intermediary where execution and continuity matter. At roughly USD 108.3 billion in market value, it sits among the larger public companies in its space.
Are rising revenues offset by thin margins?
FundamentalsFor the year ended March 31, 2025 (reported in USD), revenue was USD 359.1 billion, with EBIT of USD 4.4 billion and net income of USD 3.5 billion. Revenue grew 16.2% versus the prior annual period, while profitability remained defined by narrow spreads, including a 1.42% operating margin and a 1.09% net profit margin on a trailing basis.
Cash was USD 5.7 billion against total debt of USD 2.4 billion. Depreciation and amortization were USD 242 million and capital spending was USD 537 million, bringing the cash flow proxy to about USD 3.25 billion under the stated methodology.
Is the stock pricing in perfection?
DCF / MultiplesAt USD 884.28 per share, the stock trades below the discounted cash flow fair value range implied by the model, from a weaker scenario to a stronger outcome. Headline pricing also reflects a 24.96 trailing P/E and an 18.43 EV/EBITDA, alongside a 0.27 price-to-sales ratio.
Valuation Appears Supportive but Fragile
TakeawayThe setup depends on high-volume execution staying consistent. Thin margins leave less room for operational surprises. Cash generation needs to hold up after capital spending. If spreads compress, earnings can move quickly. Overall, the valuation looks supportive, but not without fragility.